Dr. Gayathri Nagaraj
Claim this profileLoma Linda University Cancer Center
Studies Breast Cancer
Studies Breast cancer
5 reported clinical trials
14 drugs studied
Area of expertise
1Breast Cancer
Stage IV
HER2 negative
ER positive
2Breast Cancer
Stage IV
Stage III
ER positive
Affiliated Hospitals
Clinical Trials Gayathri Nagaraj is currently running
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint High 2 Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Evexomostat + Alpelisib + Fulvestrant
for Breast Cancer
This trial tests a new drug combination for post-menopausal women with a specific type of advanced breast cancer. It aims to see if the new drug can reduce side effects and improve the effectiveness of existing treatments. The treatment works by blocking proteins and hormones that help cancer grow and by managing side effects like high blood sugar.
Recruiting1 award Phase 1 & 211 criteria
More about Gayathri Nagaraj
Clinical Trial Related2 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Gayathri Nagaraj has experience with
- Paclitaxel
- Dexamethasone
- Evexomostat
- Atezolizumab
- Pertuzumab
- Trastuzumab
Breakdown of trials Gayathri Nagaraj has run
Breast Cancer
Breast cancer
Folinic Acid Allergy
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Gayathri Nagaraj specialize in?
Gayathri Nagaraj focuses on Breast Cancer and Breast cancer. In particular, much of their work with Breast Cancer has involved Stage IV patients, or patients who are HER2 negative.
Is Gayathri Nagaraj currently recruiting for clinical trials?
Yes, Gayathri Nagaraj is currently recruiting for 3 clinical trials in Loma Linda California. If you're interested in participating, you should apply.
Are there any treatments that Gayathri Nagaraj has studied deeply?
Yes, Gayathri Nagaraj has studied treatments such as Paclitaxel, Dexamethasone, Evexomostat.
What is the best way to schedule an appointment with Gayathri Nagaraj?
Apply for one of the trials that Gayathri Nagaraj is conducting.
What is the office address of Gayathri Nagaraj?
The office of Gayathri Nagaraj is located at: Loma Linda University Cancer Center, Loma Linda, California 92354 United States. This is the address for their practice at the Loma Linda University Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.